丨证券研究报告丨 公司研究丨点评报告丨双良节能（600481.SH） [Table_Title] 费用率环比优化，经营性现金流持续为正 报告要点 [Table_Summary] 双良节能发布 2025 年半年报，2025H1 公司实现收入 43.88 亿元，同比下降 37.13%；归母净 利-5.97 亿元；其中，2025Q2 实现收入 23.09 亿元，同比下降 15.46%，环比增长 11.1%；归 母净利-4.35 亿元。 分析师及联系人 [Table_Author] 请阅读最后评级说明和重要声明 %% %% %% %% 双良节能（600481.SH） cjzqdt11111 [Table_Title2] 费用率环比优化，经营性现金流持续为正 [Table_Summary2] 事件描述 双良节能发布 2025 年半年报，2025H1 公司实现收入 43.88 亿元，同比下降 37.13%；归母净 利-5.97 亿元；其中，2025Q2 实现收入 23.09 亿元，同比下降 15.46%，环比增长 11.1%；归 母净利-4.35 亿元。 事件评论 丨证券研究报告丨 research.95579.com ...

丨证券研究报告丨 公司研究丨点评报告丨宝光股份（600379.SH） [Table_Title] 高盈利产品逐步释放，完成收购凯赛尔科技 报告要点 [Table_Summary] 公司发布 2025 年中报。上半年公司实现营业收入 6.39 亿元，同比-24.7%；归母净利润 0.4 亿 元，同比-19.0%；扣非净利润 0.36 亿元，同比-20.0%。单季度看，公司 2025Q2 营业收入 3.2 亿元，同比-28.5%，环比+0.4%；归母净利润 0.2 亿元，同比-38.0%，环比-1.5%；扣非净利润 0.2 亿元，同比-40.1%，环比-7.7%。 分析师及联系人 [Table_Author] 邬博华 曹海花 司鸿历 袁澎 SAC：S0490514040001 SAC：S0490522030001 SAC：S0490520080002 SAC：S0490524010001 SFC：BQK482 SFC：BVD284 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 宝光股份（600379.SH） cjzqdt11111 [Table_Title2] 高 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company reported a revenue of 1.949 billion yuan for the first half of 2025, representing a year-on-year growth of 1.11%. The net profit attributable to shareholders was 343 million yuan, up 10.04% year-on-year [2][4] - In Q2 2025, the company achieved a revenue of 980 million yuan, with a year-on-year increase of 0.74%, and a net profit of 140 million yuan, reflecting a significant growth of 22.24% year-on-year [2][4] - The company is experiencing robust growth in its health sector, with a notable increase in sales of its core products, particularly in the treatment of hemorrhoids, which saw a revenue growth of over 7% [10] Financial Performance - The company's gross profit margin for H1 2025 was 49.58%, an increase of 1.23 percentage points year-on-year, while the net profit margin was 17.61%, up 1.43 percentage points year-on-year [10] - The company’s operating income is projected to reach 4.267 billion yuan in 2025, with net profits expected to be 637 million yuan, 729 million yuan, and 837 million yuan for 2025, 2026, and 2027 respectively [10] Market Position and Strategy - The company is focusing on enhancing its retail capabilities and expanding into new health product categories, including functional probiotics and eye care products, which are expected to drive future growth [10] - The company has been actively investing in marketing and promotional activities to boost sales and has introduced several new products in the health sector [10]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance is in line with expectations, with a significant improvement anticipated in domestic performance in Q3 2025. The total revenue for the first half of 2025 was 16.743 billion yuan, with domestic revenue at 8.411 billion yuan, reflecting a year-on-year decline of 33.37%. This decline is attributed to the extended cycle from public bidding to revenue recognition, as the revenue corresponds to a significant drop in 2024's bidding. A recovery in hospital procurement activities is expected to lead to a performance turning point in Q3 2025 [2][13]. - The company has successfully penetrated high-end overseas markets, with overseas revenue reaching 8.332 billion yuan in the first half of 2025, a year-on-year increase of 5.39%. The overseas revenue now accounts for approximately 50% of total revenue, with significant growth in regions such as the CIS and Middle East Africa. The company plans to enhance its local production capabilities in 14 countries, with 11 already initiated, to meet overseas market demand [2][13]. - The company continues to strengthen its core competitive advantages across three main business areas. In the in-vitro diagnostics sector, revenue was 6.424 billion yuan, down 16.11% year-on-year, while overseas sales showed double-digit growth. In the medical imaging sector, revenue was 3.312 billion yuan, down 22.51% year-on-year, but is expected to recover as domestic bidding activities improve. The life information and support segment generated 5.479 billion yuan, down 31.59% year-on-year, with international revenue now constituting 67% of this segment [2][13]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved total revenue of 16.743 billion yuan, a year-on-year decline of 18.45%, with a net profit of 5.069 billion yuan, down 32.96%. The second quarter alone saw revenue of 8.506 billion yuan, down 23.77%, and a net profit of 2.440 billion yuan, down 44.55% [6][13]. Future Outlook - The company is expected to see a recovery in domestic performance in Q3 2025, driven by a resurgence in hospital procurement activities and the rollout of medical equipment updates. The overseas market is also projected to accelerate in the second half of 2025, supported by ongoing breakthroughs with high-end clients [2][13]. Business Segments - The in-vitro diagnostics segment is focusing on new product launches, with eight new chemical luminescence reagent products introduced in the first half of 2025. The medical imaging segment is expected to stabilize and grow, while the life information and support segment is expanding its international presence [2][13]. Valuation - The projected net profits for the company from 2025 to 2027 are estimated at 11.5 billion, 13.4 billion, and 15.6 billion yuan respectively, with corresponding price-to-earnings ratios of 26, 22, and 19 times [13].

丨证券研究报告丨 公司研究丨点评报告丨联影医疗（688271.SH） [Table_Title] 海外市场快速增长，市场份额持续提升 报告要点 [Table_Summary] 业绩符合预期，市场份额持续提升。2025 年上半年公司收入 60.16 亿元，其中 MR 设备实现 收入 19.68 亿元，同比增长 16.81%，3.0T 磁共振产品线在中国市场份额同比提升超 5 个百分 点。CT 设备实现收入 15.15 亿元、分子影像产品实现收入 8.41 亿元，同比增长 13.15%，公 司的 PET/CT 产品线中国市场占有率连续十年保持市场第一。海外市场订单快速增长，高端市 场持续突破。2025 年上半年公司海外收入 11.42 亿元，同比增长 22.48%，收入占比提升至 18.99%，主要是由于在北美、欧洲等关键市场均实现了多笔高价值订单的成功签约。 分析师及联系人 [Table_Author] 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 联影医疗（688271.SH） cjzqdt11111 [Table_Title2] 海外市场快速增长，市场份额持 ...

丨证券研究报告丨 港股研究丨公司点评丨理想汽车-W（2015.HK） [Table_Title] 理想汽车中报点评：业绩符合预期，看好后续产 品、销售优化带动公司反转 报告要点 [Table_Summary] 2025Q2 理想销量 11.1 万辆，同比+2.3%，实现营收 302.5 亿元，同比-4.5%，车辆毛利率达 19.4%，同比+0.6pct。理想汽车产品优势和品牌设计深入人心，后续车型规划清晰，直营渠道 结构持续优化，"双能战略"有望进一步扩大理想汽车的优势，未来销量空间广阔。 分析师及联系人 [Table_Author] 高伊楠 王子豪 SFC：BUW101 SAC：S0490517060001 SAC：S0490524070004 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 理想汽车-W（2015.HK） cjzqdt11111 [Table_Title 理想汽车中报点评：业绩符合预期，看好后续产 2] 品、销售优化带动公司反转 事件评论 丨证券研究报告丨 2025-09-09 港股研究丨公司点评 [Table_Rank]投资评级 买入丨维持 ...

[Table_Summary] 公司发布 2025 年中报。上半年公司实现营业收入 34.7 亿元，同比+40.5%；归母净利润 3.1 亿 元，同比+24.4%；扣非净利润 3.0 亿元，同比+23.3%。单季度看，公司 2025Q2 营业收入 21.7 亿元，同比+50.8%；归母净利润 1.9 亿元，同比+24.0%；扣非净利润 1.9 亿元，同比+23.5%。 丨证券研究报告丨 公司研究丨点评报告丨明阳电气（301291.SZ） [Table_Title] 营收增速亮眼，新能源与数据中心等下游或有显 著贡献 报告要点 分析师及联系人 [Table_Author] 邬博华 曹海花 司鸿历 袁澎 SAC：S0490514040001 SAC：S0490522030001 SAC：S0490520080002 SAC：S0490524010001 SFC：BQK482 SFC：BVD284 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 明阳电气（301291.SZ） cjzqdt11111 [Table_Title 营收增速亮眼，新能源与数据中心等下游或有 ...

公司研究丨点评报告丨正泰电器（601877.SH） 丨证券研究报告丨 分析师及联系人 [Table_Author] [Table_Title] 低压盈利持续修复，户用光伏快速增长 报告要点 [Table_Summary] 公司发布 2025 年中报。上半年公司实现营业收入 296.2 亿元，同比+2.2%；归母净利润 25.5 亿元，同比+32.9%；扣非净利润 25.3 亿元，同比+32.6%。单季度看，公司 2025Q2 营业收入 150.6 亿元，同比+15.2%；归母净利润 13.9 亿元，同比+65.3%；扣非净利润 14.5 亿元，同比 +64.8%。 邬博华 曹海花 司鸿历 袁澎 SAC：S0490514040001 SAC：S0490522030001 SAC：S0490520080002 SAC：S0490524010001 SFC：BQK482 SFC：BVD284 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 正泰电器（601877.SH） cjzqdt11111 [Table_Title2] 低压盈利持续修复，户用光伏快速增长 [Tab ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for investment opportunities [8]. Core Viewpoints - The past two years have seen lackluster performance for the company, but the current fundamentals suggest a potential turnaround, particularly in wind energy projects and natural gas sales [2][5]. - The company is focusing on its core wind energy business, having announced the divestment of its solar assets to concentrate on wind power, which is expected to drive growth [6][54]. - The natural gas segment is anticipated to recover despite short-term challenges, supported by the strategic importance of the Tangshan LNG project [7]. Summary by Sections Company Overview - The company is a leading clean energy enterprise in North China, primarily engaged in wind and natural gas power generation, with natural gas accounting for over 60% of its revenue [5][14]. - The company has a total installed capacity of 6.96 million kilowatts, with wind power making up 95% of this capacity [6][54]. Wind Power - The company has a strategic focus on wind power, with a significant portion of its projects located in North China. The company plans to enhance its wind power capacity, particularly through high-quality offshore wind projects [6][54]. - The implementation of the 136 document policy is expected to stabilize revenue expectations for existing projects, providing a clearer outlook for profitability in the wind sector [40][53]. Natural Gas Business - The natural gas segment includes the operation of natural gas transmission and distribution facilities, with a projected sales volume of 5.89 billion cubic meters in 2024, reflecting a 15.13% year-on-year increase [7]. - Despite short-term pressures from warm winter conditions affecting sales, the long-term growth trend for natural gas remains strong, supported by the strategic importance of the Tangshan LNG project [7][18]. Investment Recommendations - The report highlights the company's stable investment value, with projected earnings per share (EPS) of 0.52, 0.58, and 0.62 yuan for 2025-2027, corresponding to price-to-earnings (PE) ratios of 7.74, 6.87, and 6.44 respectively [8]. - The company is expected to maintain a dividend payout ratio above 50%, enhancing shareholder returns [25][31].

丨证券研究报告丨 报告要点 [Table_Summary] 公司 2025 年上半年实现营业收入 216.76 亿元，同比增长 3.74%；归属净利润 14.21 亿元，同 比增长 1.56%；扣非后归属净利润 12.39 亿元，同比减少 11.60%。 分析师及联系人 [Table_Author] 范超 张弛 李金宝 张智杰 袁志芃 SAC：S0490513080001 SAC：S0490520080022 SAC：S0490516040002 SAC：S0490522060005 SAC：S0490525070008 SFC：BQK473 SFC：BUT917 SFC：BVZ972 联合研究丨公司点评丨中材国际（600970.SH） [Table_Title] 上半年业绩微增，新签订单增速明显 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 中材国际（600970.SH） cjzqdt11111 [Table_Title2] 上半年业绩微增，新签订单增速明显 [Table_Summary2] 事件描述 丨证券研究报告丨 2025-09-09 联合研究丨公司点 ...